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INTRODUCTION
Alzheimer's disease (AD), the most prevalent neurodegenerative dementia, is characterized by gradually increasing cognitive and functional impairment. 1, 2 Along with cognitive impairment, behavioural and psychological symptoms of dementia (BPSD) are considered to be equally important, and they tend to follow a trajectory of increasing severity over time. 3, 4 These symptoms are associated with a reduced quality of life, faster cognitive decline, higher cost of care, earlier institutionalization, and high level of caregiver burden. [5] [6] [7] [8] [9] There is a growing interest in identifying the factors that contributes to the development and presence of BPSD in AD. A complex interaction of biological, psychosocial/psychological, and environmental factors have been associated with BPSD, but relatively little is known about their relationship to AD's underlying pathophysiology. 10 Cerebral ischaemia is a factor that has been postulated to influence the onset and severity of both cognitive symptoms and BPSD. White matter hyperintensities (WMH) are commonly observed on the MRI scans of AD patients and have been demonstrated to be a reliable surrogate marker for vascular pathology, mainly cerebral small vessel disease. [11] [12] [13] Some studies have found an association between BPSD and increased WMH, 14, 15 raising the possibility that these changes in the white matter may be associated with the presence and course of BPSD in AD. However, other studies have failed to find any significant association. 16, 17 Therefore, a consensus regarding the association between BPSD and WMH in AD has not been reached yet.
Medial temporal lobe atrophy (MTA) is also frequently seen on the MRI scans of AD patients. MTA is presumed to reflect disease severity because it has been related to the burden of Alzheimer's-type pathology. 18, 19 While the relationship between cognitive decline in patients with AD and volumetric reduction of the whole brain and medial temporal lobe has been well established through MRI studies, [20] [21] [22] the possible association between BPSD and MRI measures of brain atrophy deserves further exploration. Therefore, because MTA is known to progress along with dementia severity, an association, if present, would be consistent with findings from other studies, which have shown that many BPSD become more prevalent in patients with AD as disease severity increases. 23, 24 Still, it is unclear whether MTA is associated with BPSD in AD; reports about this relationship have been conflicting, and findings both for and against have been described. 14, 25, 26 The aim of this study was to assess the relationship of WMH and MTA observed on MRI with BPSD in a sample of patients with AD. We hypothesized that the presence of specific BPSD in AD could be associated with accelerated neurodegeneration as assessed by a decrease in MTA and an increase in cerebral ischaemia identified through the quantification of WMH.
METHODS

Study participants
A retrospective analysis of a prospective cohort of patients attending the Memory Clinic of the Andalusian Institute for Neuroscience in Málaga, Spain, was conducted from October 2014 to October 2016. MRI imaging was performed as the standard neuroimaging for all patients with a clinical diagnosis of dementia. Only AD patients having undergone MRI brain scan were recruited into the study.
All patients had to meet the criteria of the National Institute of Neurological and Communicative Disorders and the Stroke and the Alzheimer's Disease and Related Disorders Association for probable AD. 1 The patients were reviewed longitudinally and also retrospectively fulfilled the new criteria for probable AD with an increased level of certainty. 27 Patients were clinically defined in stages 2 to 6 of the Global Deterioration Scale. 28 Patients were excluded if there was evidence of any of the following conditions: (i) vascular dementia, such as focal neurological signs, abrupt deterioration, or stepwise progression of cognitive deficits; (ii) focal vascular lesions, such as haematomas, strokes, and normal pressure hydrocephalus; (iii) significant neurologic antecedents, such as brain trauma, brain tumours, epilepsy, or inflammatory disease; (iv) serious systemic disease such as hypothyroidism or chronic renal failure; (v) serious psychiatric diseases, substance abuse, or developmental abnormalities; and (vi) severe behavioural or communication problems that would make clinical or MRI examination difficult. Patients were also excluded if they were not accompanied by a reliable informant.
During the study period, a total of 140 patients with probable AD were identified. From these 140 subjects, potential participants were further excluded because they had insufficient documentation of dementia in their medical record (n = 28), were unable to be contacted or refused to participate (n = 37), or satisfied the exclusion criteria (n = 29).
Data on baseline demographic and vascular risk factors (e.g. any kind of heart disease, hypertension, hypercholesterolemia, or diabetes), cognitive assessment, and MRI brain parameters were collected.
The Ethical Committee of the Andalusian Institute for Neuroscience approved the study, and informed consent was obtained from patients or their caregivers.
Cognitive assessment All patients underwent neuropsychological tests to assess their cognitive function. General cognitive function was assessed using the Mini-Mental State Exam (MMSE). 29 Executive function was assessed by the letter fluency test (LFT) and the category fluency test (CFT). In the LFT, subjects were instructed to say as many words as possible that begin with the letter 'P' within 1 min. The score was the number of different words said. In the CFT, the subjects were asked to list as many animals as possible within 1 min. The score was the number of different animals listed.
Behavioural and psychological assessment The study of BPSD was carried out using the Neuropsychiatric Inventory (NPI) in its validated Spanish version. 30, 31 The NPI consists of a structured interview with the patient's caregiver. It is composed of 12 subscales that evaluate the most commonly occurring BPSD in AD patients: (i) delusions; (ii) hallucinations; (iii) agitation/aggressiveness; (iv) depression (dysphoria); (v) anxiety; (vi) euphoria; (vii) apathy/indifference; (viii) disinhibition; (xi) irritability; (x) aberrant motor activity; (xi) sleep disorders; and (xii) eating disorders. Where each subscale symptom was present, the caregiver scored it on a scale from 1 to 4 according to its frequency and from 1 to 3 with regard to its severity. A composite score for each subscale was obtained by multiplying frequency by severity, with a maximum of 12 points. Total NPI score can be obtained regarding frequency (maximum: 48 points), severity (maximum: 36 points), and composite score (maximum: 144 points). The presence of BPSD was defined as a score ≥1.
Brain MRI All MRI data were acquired on a 1.5-T General Electric Signal scanner (General Electric Medical Systems, Milwaukee, WI, USA). Images were rated by an independent trained neurologist who was blinded to the clinical data, including cognitive test results and NPI scores. WMH and MTA were studied. 
Acquisition parameters
White matter hyperintensities
Scans were made on a 1.5-T MR scanner. FLAIR and T 1 -weighted imaging were performed. The extent of WMH severity was rated visually on axial FLAIR images using the Scheltens visual rating scale for WMH ( Fig. 1 ). 32 Frontal, occipital, and lateral periventricular hyperintensities (PVH) were each rated on a scale of 0 (no hyperintensities) to 2 (severe and profuse hyperintensities), with 6 being the highest possible total PVH score. In the same way, frontal, parietal, temporal, and occipital deep subcortical hyperintensities were each rated on a scale of 0 (no hyperintensities) to 6 (severe and profuse hyperintensities), with 24 being the highest possible total DCS score. Changes in the basal ganglia, which consist of the caudate, putamen, globus pallidus, thalamus, and internal capsule, were considered as white matter lesions and were rated on a scale of 0 (no hyperintensities) to 30 (severe hyperintensities). Infratentorial lesions, which consist of the cerebellum, midbrain, pons, and medulla oblongata, were rated on a scale of 0 (no hyperintensities) to 24 (severe hyperintensities). The total WMH score for each patient was the sum of the four ratings. Patients were divided into two groups based on the presence or absence of WMH (total WMH score 0: WMH absent; total WMH score ≥1: WMH present).
Medial temporal lobe atrophy
Medial temporal lobe atrophy (MTA) was measured using the Scheltens visual rating scale for MTA. 33 The grade of MTA severity was rated visually on coronal T 1 -weighted and FLAIR images (Fig. 2 ). Left and right MTA volumes were each rated on a scale of 0 (no atrophy) to 4 (severe atrophy), with 8 being the highest possible total MTA score. The total MTA score for each patient was the sum of the two ratings. Patients were divided into two groups based on the presence or absence of MTA (total MTA score 0: MTA absent; total MTA score 1-4: MTA present).
Statistical analysis
Group comparisons were performed using two-tailed Student's t-test for parametric continuous or interval variables, two-tailed Mann-Whitney U-test for nonparametric continuous or interval variables, and χ 2 test for categorical variables. These tests were used to identify significant differences in demographics, vascular risk, and cognitive data between the groups.
For multivariate analysis, two binary logistic regression models were carried out by setting presence or absence of each BPSD as the dependent variable. Total PVH, total deep subcortical hyperintensities and total WMH were predictor variables, as were left MTA, right MTA, and total MTA. Results of the logistic regression were analyzed to see if the significance of the WMH or MTA scores was maintained in a model that factored in the possible confounding variables identified in univariate analysis. In addition, white matter scores were corrected for MTA, and the MTA grade was corrected for WMH.
Significance was set at 0.05. The statistical analyses were performed with SPSS Statistics version 20.0 (IBM Corporation, Armonk, New York, USA).
RESULTS
A total of 46 patients with mild to severe AD were studied. The subjects consisted of 24 23.58 AE 3.06, P = 0.046). No significant differences were observed with regard to age, years of education, duration of symptoms, and percentage of patients having vascular risk factors between both groups. Of the 46 patients, 37 (80.43%) were classified as having WMH and 34 (73.91%) were classified as having MTA. The combination of both WMH and MTA was observed in 28 patients (60.86%). Table 2 shows the WMH and MTA data.
The results of the NPI are given in Table 3 . The NPI mean AE SD composite score was 25.59 AE 19.99 (range: 1-112), and all the patients showed at least one symptom. Apathy was found to be the most common symptom (82.6%), followed by anxiety (73.9%), depression (69.6%), and irritability (43.5%). In contrast, euphoria was the rarest symptom (6.5%).
The results of binary logistic regression analysis showed that in models that accounted for confounding variables identified in univariate analysis, increased total MTA was significantly associated with apathy (odds ratio = 1.605, adjusted P = 0.042) and disinhibition (odds ratio = 0.607, adjusted P = 0.042) ( Table 4 ). The Hosmer-Lemeshow test was >0.05 for the two dependent variables, which indicates a good fit of the models. Models that used total PVH, total deep subcortical hyperintensities, and total WMH as predictor variables did not show that any of the WMH measures were significant at predicting any BPSD item. Infratentorial areas and basal ganglia were uncommon regions for WMH in our group with only one (2.2%) and five (10.9%) patients showing WMH, respectively. Therefore, these lesions were left out of the analysis.
DISCUSSION
In this study, we investigated the potential relationships between the presence of specific BPSD in patients with AD as assessed by the NPI and MRIbased measures of white matter changes and MTA. MTA was found to be associated with symptoms of apathy and disinhibition. These findings suggest that degeneration of the medial temporal lobe, mainly the hippocampus, may be associated with the emergence of BPSD in patients with AD, as it is with global cognitive decline and memory impairment. We did not find evidence to support the association of any specific BPSD with WMH changes.
The prevalence rates of BPSD in this sample of patients with AD were comparable to those reported in other studies in which apathy, anxiety and depression were the most prevalent. 5 In the present study, our hypothesis that the presence of BPSD was associated with increased MTA in patients with AD was supported in the case of apathy and disinhibition, suggesting that MTA is an important correlate of these symptoms. Symptoms of disinhibition are relatively rare in AD, but still occur in 24-33% of cases, 34 as was seen in the current sample (17%). These symptoms have been associated with advanced dementia severity and reduced brain volume. 24, 35 In contrast, apathy is one of the most frequent manifestations of AD, 36, 37 and the present findings suggest this symptom may be linked to common pathological processes occurring in the brain of AD patients.
In AD, regional associations between brain changes and BPSD have been proposed. In the case of apathy in dementia, previous studies have investigated the anatomical correlates of apathy in terms of loss of grey matter, WMH, neuritic plaque, neurofibrillary tangles, and lesions in white matter tracts, but contradictory results have been published. In a study carried out in 29 subjects with definitive AD, chronic NPI apathy scores correlated with anterior cingulate neurofibrillary tangle counts. This analysis suggests that chronic apathy in AD correlates with a greater anterior cingulate neurofibrillary tangle burden and that chronic behavioural changes are more reflective of disease pathology than acute changes. 38 Some studies have reported correlations between apathy and damage in different areas-namely, the cingulum, 39 thalamus, parietal regions, 40,41 right superior longitudinal fasciculus, and bilateral uncinate fasciculus or anterior thalamic radiation. 42, 43 More recently, a study showed that bilateral damage to the corpus callosum and internal capsule was associated with apathy severity and that structural correlates of apathy differed between the three apathy dimensions (deficit of thinking and self-generated behaviours, emotional blunting, and cognitive inertia) in patients with advanced AD. 44 In AD patients, a decrease of hippocampal volume has been related to the extent of Alzheimer's-type neuropathology. 18 In this sense, our results showing a significant relationship between MTA and both apathy and disinhibition suggest that the degeneration of the medial temporal lobe may be closely correlated with the emergence of some BPSD in AD, as it is with global cognitive decline and memory impairment. In addition, in our study, MTA is also related to MMSE, CFT, and LFT. These parameters could have affected the relationship between MTA and apathy and between MTA and disinhibition in our sample. These findings suggest that the pathophysiological processes responsible for cognitive decline in AD may also be related to the processes underlying the emergence of BPSD at least in earlier stages of dementia.
We were unable to replicate previously reported associations between WMH and specific BPSD in patients with AD. 14, 16, 17 This may be in part due to our use of visual rating scales instead of volumetric measures to quantify WMH load. 14, 44 Volumetric measuring techniques have the advantage of being unbiased and robust in their reliability, and they have been reported to be more sensitive than visual rating scales at detecting relationships between WMH and clinical measures. 45 Another possible source for discrepancies with previous studies could be explained by the populations of these studies, which included patients with more severe dementia than our patients, suggesting a possible role of vascular mechanisms leading to cognitive deterioration and BPSD in the advanced stages of AD. 26, 44 However, in our sample only two patients (4.3%) were at the more impaired levels (MMSE ≤ 10), and this could explain why brain lesions related to apathy may be different in the advanced stages of AD compared to milder forms of the disease. Moreover, some studies have shown that patients with AD and patients with vascular dementia have similar neuropsychiatric profiles. 46 This provides further support for our results: within a group of AD patients, additional vascular involvement, measured as WMH, does not influence the behavioural and psychological profile.
In patients with AD, white matter lesions observed on MRI have been reported to be associated with impaired frontal lobe function, 47 and the lesions of the dorsolateral prefrontal circuit mainly involved in executive function are associated with impaired recall and deficient executive strategy performances, as the performances of the LFT and CFT show. 48, 49 For instance, in a study examining the association between cognitive function and BPSD assessed by NPI, LFT and CFT scores were significantly associated with changes in the psychosis subdomain. 50 Unlike these findings, our results found no significant differences between patients with and without WMH on the LFT, CFT, or MMSE, which could in part explain the lack of association between WMH and specific BPSD. This study had some limitations. First, it was a retrospective study with a relatively small sample size. However, these findings will be important for the design of a prospective longitudinal study. Second, to measure the extent of WMH and MTA, we used visual rating scales, which may not be as accurate as the MRI volumetric method. However, the Scheltens rating scales, which were used in the present study, are widely accepted and have been shown to provide good global assessments of WMH and MTA. In addition, simple rating scales, such as the Scheltens scales, have been shown to be comparable with complex measures of WMH in terms of associations with clinical outcome measures. 51 Furthermore, to ensure the interrater reliability of the scale, two blind investigators should have scored both WMH and MTA. Third, the study results might have been biased because all patients were recruited from only one dementia clinic. From here, further studies will be needed to determine and explore the nature of the relationship of BPSD in AD patients with white matter disease and MTA. Additionally, a longitudinal study will be able to better track changes in BPSD over time and determine how they relate to changes in the severity of dementia, white matter disease, and MTA.
In conclusion, changes to the medial temporal lobe were associated with symptoms of apathy and disinhibition in patients with AD. These findings indicate that MTA potentially contributes to the aetiology of these symptoms, and they provide evidence to support the hypothesis that AD pathology itself can contribute to BPSD. Our study failed to detect associations of any BPSD with WMH, suggesting that BPSD in AD may progress independently of cerebral small vessel disease. Additional studies investigating these relationships may provide insight to future directions for the diagnosis and treatment of BPSD in AD.
